LLY Healthcare

Eli Lilly & Co.

$1078.52
+3.58% (+$37.23)
Valuation Metrics
P/E Trailing --
P/E Forward --
PEG Ratio --
Market Cap --
Price Target --
Balance Sheet
D/E Ratio --
Current Ratio --
Cash --
Total Debt --
Net Cash --
Profitability
Gross Margin --
Operating Margin --
Net Margin --
ROE --
FCF --
Scores
GF Score --
Altman Z-Score --
Piotroski F-Score --
Div. Yield --
Analyst Rating --
Analysis & Conclusion BEARISH
STRONG_SELL

STRONG SELL: Metrics within normal ranges.

Recent News
Dow Jones Futures: Stocks Jump As Trump Halts Greenland Tariffs; Google, Eli Lilly Lead 8 New Buys

Stocks rebounded as President Donald Trump said he won't go ahead with Greenland tariffs, citing a "framework" for a future deal. Google and Eli Lilly lead new buys.

Investor's Business Daily •
Why Eli Lilly Is The IBD Stock Of The Day — Again — As Its Novo Nordisk Rivalry Deepens

Eli Lilly is Wednesday's IBD Stock Of The Day. Lilly shares are bounding off their 50-day line with a new buying opportunity in sight.

Investor's Business Daily •
Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +1.05% and +1.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for …

Zacks •
Why Eli Lilly (LLY) Stock Is Up Today

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation for its drug, …

StockStory •
FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate

Eli Lilly wins FDA Breakthrough Therapy status for sofetabart mipitecan in certain patients with platinum-resistant ovarian cancer.

Zacks •
Is Eli Lilly (LLY) Pricing Look Stretched After A Strong Multi Year Share Price Run

If you are wondering whether Eli Lilly's current share price reflects its true worth, you are not alone. This article is built to help you frame that question clearly. The …

Simply Wall St. •
Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention

TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.

Zacks •
Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies

Amgen Inc. (NASDAQ:AMGN) is one of the best undervalued wide moat stocks. On January 13, 2026, an announcement came regarding the Ro and Amgen Inc. (NASDAQ:AMGN) collaboration. Ro, a U.S. …

Insider Monkey •
AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market

AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its …

Insider Monkey •
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026?

Despite a challenging year, the company has a lot to look forward to in the coming years.

Motley Fool •